Abstract: Provided is a method and a composition for improving behavioral performance in an individual comprising identifying an individual in need of treatment, and providing such an individual a composition comprising bacteria within the genus Bacteroides.

Abstract: A single dissolving compound forms plural azeotropes, which can be azeotropically vaporized off at various stages of the treatment process, thus maintaining predictable concentrations of the chemicals present. The treatment process can be performed in the absence of formalin or related compounds which can interfere with the preservation of genetic material. A process for preserving a specimen includes using a dissolving compound that can form a plural number of azeotropes, at least one azeotrope being formed between one or more components of the dissolving compound and specimen-supplied water, and at least one azeotrope being formed between different components of the dissolving compound; successively and azeotropically vaporizing off formed azeotropes; and impregnating the specimen with a support medium.

Abstract: The present invention relates to a process of converting carbon dioxide using a combination of a carbon dioxide mineralization and the metabolism of sulfur-oxidizing microorganisms. According to the process, a carbonate produced in the carbon dioxide mineralization reaction can be converted to a useful substance without supplying an external additional energy source (light, electrical energy, etc.) and mineral resources (metal ions). In addition, the process can be continuously performed by recycling metal ions necessary for the carbon dioxide mineralization reaction.

Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.

Abstract: The present invention is directed to a novel isolated bacterial strain of the Lactobacillus casei (L. casei) species. More in particular, the strain of the Lactobacillus casei species deposited under accession number LMG P-30039. The present invention further relates to the novel L. casei strain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novel L. casei strain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novel L. casei strain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of a L. casei species that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of said L.

Abstract: The present disclosure relates to a composition for preventing, relieving or treating climacteric symptoms, the composition comprising lactic acid bacteria and prebiotic composition. The lactic acid bacteria of the present disclosure have ?-glucosidase activity and a very excellent ability to convert isoflavones into equol compounds, and thus may exhibit estrogenic activity through synergism with the gut microbiota. Therefore, the lactic acid bacteria of the present disclosure may be effectively used for the prevention, relief or treatment of women's climacteric or menopausal symptoms.

Abstract: A process is provided for bioconversion of carbon monoxide and carbon dioxide. More specifically, the process includes fermenting carbon monoxide and carbon dioxide containing substrate with acetogenic bacteria. The process provides for high levels of carbon monoxide and carbon dioxide conversions and utilization of hydrogen.

Abstract: Technologies for cryopreserving ungulate embryos for implantation into recipient females are described.

Abstract: The present invention provides novel Lactobacillus sp. strains, novel Bifidobacterium sp. strains, or lactic acid bacteria mixtures thereof, which are isolated from kimchi or human feces. A certain Lactobacillus sp. strain or certain Bifidobacterium sp. strain according to the present invention is isolated from kimchi or human feces, and thus is highly safe, and has various physiological activities such as antioxidant activity, ?-glucuronidase inhibitory activity, lipopolysaccharide (LPS) production inhibitory activity or tight junction protein expression-inducing activity. Accordingly, a certain Lactobacillus sp. strain, certain Bifidobacterium sp. strain or mixture thereof according to the present invention may be used as a functional food or medicinal material useful for the prevention, alleviation or treatment of intestinal damage, liver injury, allergic disease, inflammatory disease, or obesity.

Abstract: A CO2, bioconversion process includes providing a CO2 containing substrate to a bioreactor, the CO2 containing substrate including about 5 to about 90 mole % CO2; and fermenting the CO2 containing substrate with an acetogenic bacteria carrying a sodium translocating ATPase. The medium including less than about 0.01 grams per liter yeast extract, less than about 0.01 grams per liter carbohydrate, a sodium ion concentration provided by a sodium ion feed rate of about 290 to about 8750 ?g/gram of cells/minute, and a pH of about 4 to about 6.9.

Abstract: Particularly effective prebiotic-probiotic combinations including a novel probiotic, B. longum subsp longum, and XOS and B. pseudocatenulatum with Xylo-oligosaccharides are provided, together with methods of identifying synergistic probiotic-prebiotic combinations. Additionally, kits comprising the probiotic(s) and prebiotic(s) are also provided.

Abstract: Provided herein are methods of recovering oil from microorganisms. The methods are useful, for example, in obtaining nutritional oils and/or lipid biofuels. The methods of recovering oil described herein include contacting a population of microorganisms with one or more enzymes under conditions that cause disruption of the microorganisms, concentrating the disrupted microorganisms, and extracting lipids from the disrupted microorganisms at high temperature in the presence of a salt and in the absence of solvent.

Abstract: The present invention relates to a method for mimicking the effects of ionizing radiations on cells, wherein cells are contacted with bleomycin.

Abstract: The invention pertains to a blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings of patients having an acquired coagulation factor deficiency or for use in the treatment or prophylaxis of bleedings of patients having a congenital deficiency of a coagulation factor. Said product comprises at least isolated prothrombin (Factor II) and isolated Antithrombin III (ATIII), whereby the molar ratio between ATIII to Factor II is at least 1:30. By administration of said product the patient's risk for a thromboembolic complication is reduced.

Abstract: The invention relates to a pharmaceutical and/or dietetic composition for increasing the impact of the immune defense of higher living beings, wherein bacteria of the species Lactobacillus fermentum from at least one of the strains K1-Lb1 or K1-Lb6 or K2-Lb4 or K6-Lb4 or K7-Lb1 or K8-Lb1 or K9-Lb6 are contained in order to control the adaptive and natural immune defense by means of T helper 1 and T helper 2 cells and/or bacteria of the species Lactobacillus fermentum from at least one of the strains K2-Lb6 or K11-Lb3 are contained in order to strengthen the native immune defense.

Abstract: A microbe-specific medium, containing specific chromogenic substrates, for the detection of vancomycin-resistant enterococci in a biological sample, whereby both the detection and identification of vancomycin-resistant enterococci at the species level is achieved utilizing one sample and one test.

Abstract: The invention relates to a method for the protein enrichment of a heterotrophically cultured microalga, the microalga being of the genus Chlorella, even more particularly Chlorella protothecoides, characterized in that it comprises: a first step directed toward limiting the ammonium supply so as to obtain a microalgal biomass with a protein content of less than 50% expressed as N.6.25, preferably less than 30%, more preferentially between 20 and 25%; a second step in which the ammonium supply in the fermentation medium is increased so as to obtain a protein content of greater than 50%, preferably greater than 60%, more preferentially greater than 65%.

Abstract: The present disclosure relates to the field of microbial technology, and discloses a composite probiotics and the use thereof. The composite probiotics in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631, Lactobacillus rhamnosus CCFM1044 and Lactobacillus casei CCFM711, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering contents of serum low density lipoprotein, total cholesterol, and liver triglyceride and contents of serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and IFN-?, and increasing contents of liver glutathione and superoxide dismutase, etc. The extent of decrease or increase is increased by 7.91% to 837.31% compared with the formulations of CCFM8630 or CCFM8631 alone or combination of the two probiotics. The combination of the four probiotics can achieve a significant synergistic effect.

Abstract: Provided is an agent having an action on a transcellular ion transporter in the intestinal tract, the agent containing a bacterium of the genus Bifidobacterium or the genus Lactobacillus, or a treated product thereof, with the proviso that the case where the ion transporter is a chloride channel and the action is inhibition; the case where the ion transporter is Na+K+Cl? cotransporter (NKCC1) and the action is inhibition; the case where the bacterium is Bifidobacterium infantis 35624; and the case where the bacterium is Lactobacillus salivarius UCC118 are excluded. The agent of the present invention is useful in activation of chloride channels, prevention or treatment of renal diseases, and/or promotion of defecation, and therefore, usable as a medicament, a supplement, etc.

Abstract: The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.